Neurotoxicity Clinical Trial
Official title:
Sirolimus Switching From Calcinurin Inhibitors (CNI) 90 - 180 Days After Liver Transplantation
Verified date | January 2017 |
Source | Thomas Jefferson University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Observational |
Sirolimus can be safely switched as early as 90 days after liver transplantation with excellent tolerability and amelioration of the calcineurin inhibitor toxicity that initiated the switch.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | January 2010 |
Est. primary completion date | January 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Adult (18 years or older) patients undergoing liver transplantation at Thomas Jefferson University Hospital. 2. Diagnosed with at least one of the following CNI side effects 90-180 days post transplantation: 1. CNI renal toxicity. Any liver transplant recipient who has elevated creatinine level (greater than 1.4 mg/dl) and impaired creatinine clearance (MDRD) of 40-60 ml/minute or decreased by 15% compared to baseline in the setting of having a therapeutic CNI level, without suspicion of acute or chronic allograft rejection. 2. Hepatic fibrosis on biopsy. Any patient who has fibrosis seen on liver biopsy with LFT's 2 times the upper normal limit. 3. CNI neurologic toxicity. Any patient who has significant neurological side effects from CNIs. This will include the following: seizures not secondary to an epileptogenic focus or any metabolic derangement; alteration of speech ranging from aphasia to slurred speech; inability to be awake and alert. 4. Post transplant diabetes. Any patient who has developed diabetes after transplant and in whom CNIs are thought to be contributing to poor glycemic control. 3. Signed informed consent at approximately 90 -180 days post transplantation. Exclusion Criteria: 1. Invasive/surgical therapy within 2 weeks of the 90-180 day post transplantation conversion. (e.g. patients with T-tubes would not be eligible for the study because the T-tube removal will coincide with the conversion date). 2. Open surgical wound at 90-180 days post transplantation. 3. Acute cellular rejection during the first 90-180 days post transplantation. 4. Re-transplants or multiple-organ transplants. 5. Active infection. 6. Pregnancy. 7. Malignancy within 3 years prior to liver transplantation (except adequately treated basal cell carcinoma). Patients with HCC prior to transplant will not be excluded. 8. Total cholesterol >300 mg/dl on medical treatment or triglycerides >150 mg/dl at 90-180 days post transplantation. 9. White blood cell count <3,000/mm3 or platelet count <100,000/mm3 at 90-180 days post transplantation. 10. Ascites. 11. Patients on chemotherapy. 12. Urine protein/creatinine ration > 0.5 |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | THomas Jefferson University and Hospital | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Thomas Jefferson University | Wyeth is now a wholly owned subsidiary of Pfizer |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary objective is that acute cellular rejection following a switch to sirolimus will be comparable to the historical rate at our center under calcineurin inhibitors of around 5% for post liver transplant recipients. | 12 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05510596 -
Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome
|
N/A | |
Completed |
NCT01399372 -
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
|
Phase 2 | |
Completed |
NCT01196442 -
Electrical Stimulation Pain Therapy in Treating Chronic Pain and Numbness Caused By Chemotherapy in Patients With Cancer
|
N/A | |
Completed |
NCT00775645 -
S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy
|
Phase 3 | |
Recruiting |
NCT00884767 -
Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
|
Phase 2 | |
Recruiting |
NCT03330964 -
Clinical Trial of Electroacupuncture Stimulation on Prevention and Treatment of Oxaliplatin Neurotoxicity
|
N/A | |
Active, not recruiting |
NCT04150913 -
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
|
Phase 2 | |
Completed |
NCT01417507 -
Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery
|
N/A | |
Completed |
NCT00471445 -
Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients
|
Phase 3 | |
Completed |
NCT00365768 -
Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors
|
Phase 2 | |
Withdrawn |
NCT00734773 -
Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL
|
Phase 0 | |
Completed |
NCT00305799 -
Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors
|
N/A | |
Completed |
NCT00018967 -
Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate
|
N/A | |
Active, not recruiting |
NCT00978458 -
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
|
Phase 3 | |
Completed |
NCT05094154 -
Effect of Antibiotic Choice On ReNal Outcomes (ACORN)
|
Phase 4 | |
Completed |
NCT02486198 -
Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer
|
Phase 3 | |
Not yet recruiting |
NCT05798884 -
Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients
|
N/A | |
Completed |
NCT02864030 -
PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
|
Phase 4 | |
Completed |
NCT00755313 -
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
|
N/A | |
Completed |
NCT00369564 -
Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer
|
Phase 3 |